Results 61 to 70 of about 111,907 (307)

Sestrin2 Signaling Pathway Regulates Podocyte Biology and Protects against Diabetic Nephropathy

open access: yesJournal of Diabetes Research, 2023
Sestrin2 regulates cell homeostasis and is an upstream signaling molecule for several signaling pathways. Sestrin2 leads to AMP-activated protein kinase- (AMPK-) and GTPase-activating protein activity toward Rags (GATOR) 1-mediated inhibition of ...
Moein Ala
doaj   +1 more source

Late‐Stage Functionalization of Peptides on the Solid Phase

open access: yesAngewandte Chemie International Edition, EarlyView.
Peptide modifications are essential to control pharmacodynamic and pharmacokinetic properties of peptide drugs. Consequently, strategies that allow for efficient and rapid incorporation of non‐canonical modifications into peptides in parallel formats are highly sought after.
Marius Werner   +2 more
wiley   +1 more source

Redox Signaling in Diabetic Nephropathy: Hypertrophy versus Death Choices in Mesangial Cells and Podocytes

open access: yesMediators of Inflammation, 2015
This review emphasizes the role of oxidative stress in diabetic nephropathy, acting as trigger, modulator, and linker within the complex network of pathologic events.
Gina Manda   +3 more
doaj   +1 more source

Multi‐Omic Profiling Reveals Immune Cell Priming Signature Linked to Lupus Prognosis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Systemic lupus erythematosus (SLE) is a multiorgan disease with widespread immune dysregulation and significant unmet clinical need. Blood‐based gene expression studies have advanced our understanding of SLE pathogenesis but may overlook critical tissue‐specific mechanisms that drive disease heterogeneity and progression.
Michael A. Smith   +23 more
wiley   +1 more source

Potensi Kedelai sebagai Nutrisiuntuk Pencegahan Nefropati Diabetes pada Penderita Diabetes Melitus

open access: yesNERS Jurnal Keperawatan, 2015
Diabetes mellitus is the fourth of five causes of death in developed countries . This trend extends to developing countries and newly industrialized countries .
Putri Dafriani
doaj   +1 more source

Vasopressin and diabetic nephropathy [PDF]

open access: yesCurrent Opinion in Nephrology and Hypertension, 2017
The prevalence of diabetic kidney disease (DKD) is increasing worldwide. Despite major therapeutic advances in the last decades in DKD, the current standard of care let many people progress to severe stages. Vasopressin secretion is increased in diabetes, and its potential role in the onset and progression of DKD is being re-investigated.Recently ...
Roussel, Ronan   +2 more
openaire   +2 more sources

Serum levels of advanced glycation endproducts and other markers of protein damage in early diabetic nephropathy in type 1 diabetes [PDF]

open access: yes, 2012
Objective To determine the role of markers of plasma protein damage by glycation, oxidation and nitration in microalbuminuria onset or subsequent decline of glomerular filtration rate (termed “early GFR decline”) in patients with type 1 diabetes ...
Weston Andrew   +35 more
core   +1 more source

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova   +5 more
wiley   +1 more source

The Heart and Diabetic Nephropathy

open access: yesMethodist DeBakey Cardiovascular Journal, 2010
BACKGROUND Diabetic nephropathy represents the most common etiology for stage 5 chronic kidney disease in the United States, resulting in the need for dialysis and transplantation. It is estimated that about one-third of U.S. patients who need renal replacement therapy are diabetics.
Juan Jorge, Olivero   +3 more
openaire   +3 more sources

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy